

herewith.

IN THE CLAIMS:

Please cancel claims 8, 12, 14, 17, and 25.

Please amend claims 1, 9 and 15 to read as follows.

1. (Amended) A conjugate consisting essentially of at least one antibody fragment covalently attached to no more than about 2 nonproteinaceous polymer molecules, wherein the apparent size of the conjugate is at least about 500 kD, wherein the antibody fragment comprises a heavy chain and a light chain corresponding to a portion of a parental antibody, wherein in the portion of the parental antibody the heavy and light chains are covalently linked by a disulfide bond between a cysteine residue in the light chain and a cysteine residue in the heavy chain, wherein in the antibody fragment the cysteine residue in the light or heavy chain is substituted with another amino acid and the cysteine residue in the opposite chain is covalently linked to a nonproteinaceous polymer molecule, and wherein at least one antibody fragment comprises an antigen binding site that binds to a polypeptide selected from the group consisting of: human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human Apo-2 receptor, human tumor necrosis factor- α (TNF- α), human tissue factor (TF), human α 4 β 7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α -chain (TAC).

2. 9. (Amended) The conjugate of claim 1 wherein the antibody fragment is F(ab')₂.

3. 15. (Amended) The conjugate of claim 1 wherein the antibody fragment is selected from the group consisting of Fab, Fab' and Fab'-SH.

Marked-up versions of the amended claims are shown on a separate paper enclosed herewith.